Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress

Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress NEWS PROVIDED BY Alphyn Biologics Apr 27, 2023, 07:30 ET ANNAPOLIS, Md., April 27, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, will present for the first time new pediatric data from its Phase…

Empowered Patient Podcast: Treating Atopic Dermatitis with Neal Koller, CEO, Alphyn Biologics

Empowered Patient Podcast: Treating Atopic Dermatitis Using Therapeutic Drug Containing Multiple Bioactive Compounds with Neal Koller Alphyn Biologics NEWS PROVIDED BY Alphyn Biologics Feb 27, 2023 Neal Koller, CEO of Alphyn Biologics, discusses their first topical drug which treats both atopic dermatitis and atopic dermatitis with secondary infection.   Listen to the podcast here. CONTACTS…

Cincinnati Business Courier: Queen City Angels-backed Alphyn eyes another fundraise amid ‘positive’ clinical study results

Cincinnati Business Courier: Queen City Angels-backed Alphyn eyes another fundraise amid ‘positive’ clinical study results by Liz Engel NEWS PROVIDED BY Alphyn Biologics January 11, 2023 Alphyn Biologics, a clinical-stage dermatology company developing a new class of drugs for skin diseases, will pursue a Series B financing round in 2023. Read the Cincinnati Business Courier…

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Jan 4, 2023, 07:30 ET ANNAPOLIS, Md., Jan. 4, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase…